Cover Image
市場調查報告書

全球感染疾病治療市場

Global Infectious Disease Treatment Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 232696
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
全球感染疾病治療市場 Global Infectious Disease Treatment Market 2014-2018
出版日期: 2014年08月27日 內容資訊: 英文 150 Pages
簡介

全球感染疾病治療市場,從2013年到2018年,預計以年複合成長率3.43%擴大。

本報告提供全球感染疾病治療市場調查、市場趨勢與成長預測、主要供應商分析等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 各應用領域的市場區隔

第8章 全球抗菌藥市場

  • 簡介
  • 市場規模與預測
  • 各化學分類的市場區隔
  • 各藥物來源的市場區隔

第9章 全球抗真菌藥物市場

  • 簡介
  • 市場規模與預測
  • 各化學分類的市場區隔
  • 各地區的市場區隔
    • 美國的抗真菌藥物市場
    • 歐洲的抗真菌藥物市場

第10章 全球抗病毒藥物市場

  • 簡介
  • 市場規模與預測
  • 各疾病的市場區隔
  • 全球C型肝炎治療藥市場
  • 全球C型肝炎治療藥市場
  • 全球HIV治療藥市場

第11章 全球抗寄生蟲藥市場

  • 市場規模與預測

第12章 地理區隔

第13章 購買標準

第14章 市場成長因素

第15章 成長因素與其影響

第16章 市場課題

第17章 成長因素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Gilead Sciences
    • GlaxoSmithKline
    • Pfizer
    • F. Hoffmann-La Roche
    • Johnson & Johnson
    • Merck
  • 其他卓越供應商

第21章 主要供應商分析

  • F. Hoffmann La Roche
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck
  • Pfizer

第22章 相關報告

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR4063

About Infectious Disease Treatment

Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. Anti-infective drugs can act via host defence system or can directly target the causative agent.

TechNavio's analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Infectious Disease Treatment market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include:

Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials)

  • Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals)
  • Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs)
  • Antiparasitic drugs

TechNavio's report, the Global Infectious Disease Treatment Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Infectious Disease Treatment market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Pfizer

Other Prominent Vendors

  • Achillion Pharmaceuticals
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Auritec Pharmaceuticals
  • Bayer
  • Bristol-Myers Squibb
  • Chimerix Pharmaceuticals
  • Cubist
  • Eli Lilly
  • Isis Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis
  • pSivida
  • Sanofi

Market Driver

  • Launch of Direct Acting Antivirals

For a full, detailed list, view our report

Market Challenge

  • Generic Erosion

For a full, detailed list, view our report

Market Trend

  • Emergence of IFN-free Therapies

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Application

08. Global Antibacterial Drugs Market

  • 08.1. Introduction
  • 08.2. Market Size and Forecast
  • 08.3. Market Segmentation by Chemical Class
  • 08.4. Market Segmentation by Drug Origin

09. Global Antifungal Drugs Market

  • 09.1. Introduction
  • 09.2. Market Size and Forecast
  • 09.3. Market Segmentation by Chemical Class
  • 09.4. Market Segmentation by Geography
    • 09.4.1. Antifungal Drugs Market in the US
    • 09.4.2. Antifungal Drugs Market in Europe

10. Global Antiviral Drugs Market

  • 10.1. Introduction
  • 10.2. Market Size and Forecast
  • 10.3. Market Segmentation by Disease
  • 10.4. Global Hepatitis C Drugs Market
    • 10.4.1. Market Size and Forecast
    • 10.4.2. Geographical Segmentation
  • 10.5. Global Hepatitis B Drugs Market
    • 10.5.1. Market Size and Forecast
  • 10.6. Global HIV Drugs Market
    • 10.6.1. Market Size and Forecast

11. Global Antiparasitic Drugs Market

  • 11.1. Market Size and Forecast

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
    • 20.2.1. Gilead Sciences
    • 20.2.2. GlaxoSmithKline
    • 20.2.3. Pfizer
    • 20.2.4. F. Hoffmann-La Roche
    • 20.2.5. Johnson & Johnson
    • 20.2.6. Merck
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. F. Hoffmann La Roche
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Business Segmentation by Revenue 2012 and 2013
    • 21.1.5. Geographical Segmentation by Revenue 2013
    • 21.1.6. Business Strategy
    • 21.1.7. Recent Developments
    • 21.1.8. SWOT Analysis
  • 21.2. Gilead Sciences
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Geographical Segmentation by Revenue 2013
    • 21.2.4. Recent Developments
    • 21.2.5. SWOT Analysis
  • 21.3. GlaxoSmithKline plc
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Pipeline Products
    • 21.3.7. Business Strategy
    • 21.3.8. Key Information
    • 21.3.9. SWOT Analysis
  • 21.4. Johnson & Johnson
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Business Segmentation by Revenue 2013
    • 21.4.4. Business Segmentation by Revenue 2012 and 2013
    • 21.4.5. Geographical Segmentation by Revenue 2013
    • 21.4.6. Business Strategy
    • 21.4.7. Recent Developments
    • 21.4.8. SWOT Analysis
  • 21.5. Merck
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Business Segmentation by Revenue 2013
    • 21.5.4. Business Segmentation by Revenue 2012 and 2013
    • 21.5.5. Sales by Geography
    • 21.5.6. Business Strategy
    • 21.5.7. Key Developments
    • 21.5.8. SWOT Analysis
  • 21.6. Pfizer
    • 21.6.1. Key Facts
    • 21.6.2. Business Description
    • 21.6.3. Business Segmentation
    • 21.6.4. Revenue by Business Segmentation
    • 21.6.5. Revenue Comparison 2012 and 2013
    • 21.6.6. Sales by Geography
    • 21.6.7. Business Strategy
    • 21.6.8. Key Developments
    • 21.6.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Infectious Disease Treatment Market 2013-2018 (US$ million)
  • Exhibit 3: Global Infectious Disease Treatment Market Segmentation by Application
  • Exhibit 4: Global Infectious Disease Treatment Market Segmentation by Application 2013
  • Exhibit 5: Global Infectious Disease Treatment Market Segmentation by Application 2018
  • Exhibit 6: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018 (US$ million)
  • Exhibit 7: Global Infectious Disease Treatment Market Segmentation by Application 2013-2018
  • Exhibit 8: Snapshot of Global Infectious Disease Treatment Market Segments 2013-2018
  • Exhibit 9: YoY Growth Rate of Global Infectious Disease Treatment Market Segments 2013-2018
  • Exhibit 10: Global Antibacterial Drugs Market: Key Drivers and Challenges
  • Exhibit 11: Global Antibacterial Drugs Market 2013-2018 (US$ million)
  • Exhibit 12: Global Antibacterial Drugs Market Segmentation by Chemical Class
  • Exhibit 13: Cephalosporin Segmentation by Generation of Drugs
  • Exhibit 14: Global Antibacterial Drugs Market Revenue Segmentation by Chemical Class 2013
  • Exhibit 15: Global Antibacterial Drugs Market Segmentation by Chemical Class in Volume 2013
  • Exhibit 16: Global Antibacterial Drugs Market Segmentation by Drug Origin
  • Exhibit 17: Global Antifungal Drugs Market: Key Drivers and Challenges
  • Exhibit 18: Global Antifungal Drugs Market 2013-2018 (US$ million)
  • Exhibit 19: Global Antifungal Drugs Market Segmentation by Chemical Class
  • Exhibit 20: Global Antifungal Drugs Market Segmentation by Chemical Class 2013
  • Exhibit 21: Global Antifungal Drugs Market by Geography Segmentation 2013
  • Exhibit 22: Antifungal Drugs Market in the US 2013-2018 (US$ million)
  • Exhibit 23: Antifungal Drugs Market in Europe 2013-2018 (US$ million)
  • Exhibit 24: Global Antiviral Drugs Market: Key Drivers and Challenges
  • Exhibit 25: Global Antiviral Drugs Market 2013-2018 (US$ million)
  • Exhibit 26: Global Antiviral Drugs Market Segmentation by Disease
  • Exhibit 27: Global Antiviral Drugs Market Segmentation by Disease 2013
  • Exhibit 28: Global Antiviral Drugs Market Segmentation by Disease 2018
  • Exhibit 29: Global Hepatitis C Drugs Market 2013-2018 (US$ million)
  • Exhibit 30: Global Hepatitis C Market by Geographical Segmentation 2013
  • Exhibit 31: Global Hepatitis B Drugs Market 2013-2018 (US$ million)
  • Exhibit 32: Global HIV Drugs Market 2013-2018 (US$ million)
  • Exhibit 33: Global Antiparasitic Drugs Market: Key Drivers and Challenges
  • Exhibit 34: Global Antiparasitic Drugs Market 2013-2018 (US$ million)
  • Exhibit 35: Global Infectious Disease Treatment Market by Geographical Segmentation 2013
  • Exhibit 36: Global Infectious Disease Treatment Market Share Analysis 2013
  • Exhibit 37: Revenue of Stribild 2012-2013 (US$ million)
  • Exhibit 38: Revenue of Truvada 2011-2013 (US$ million)
  • Exhibit 39: Revenue of Emtriva 2011-2013 (US$ million)
  • Exhibit 40: Revenue of Atripla 2011-2013 (US$ million)
  • Exhibit 41: Revenue of Complera/Eviplera 2011-2013 (US$ million)
  • Exhibit 42: Revenue of Viread 2011-2013 (US$ million)
  • Exhibit 43: Revenue of Hepsera 2011-2013 (US$ million)
  • Exhibit 44: Revenue of AmBisome 2011-2013 (US$ million)
  • Exhibit 45: Gilead Sciences: Percentage Share of Key Antiviral Drugs 2013
  • Exhibit 46: Share of Key Antiviral Drugs in Gilead Sciences' Revenue 2013
  • Exhibit 47: Gilead Sciences: Percentage Share of Key Anti-infective Drugs 2011-2013
  • Exhibit 48: Gilead Sciences: Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
  • Exhibit 49: Gilead Sciences: Revenue Trend of Key Anti-infective Drugs 2011-2013
  • Exhibit 50: Gilead Sciences' Key Anti-infective Drugs 2011-2013
  • Exhibit 51: Share of GlaxoSmithKline's Anti-infective Segment 2013
  • Exhibit 52: GlaxoSmithKline's Key Antiviral Drugs Portfolio
  • Exhibit 53: Share of Key Antiviral Drugs in GlaxoSmithKline's Antiviral Drugs Segment 2013
  • Exhibit 54: Geography-wise Segmentation of GlaxoSmithKline's Antiviral Drugs Segment 2013
  • Exhibit 55: Geography-wise Segmentation of GlaxoSmithKline's Key Anti-viral Drugs 2013
  • Exhibit 56: Geography-wise Segmentation of GlaxoSmithKline's Key Anti-viral Drugs 2013 (US$ million)
  • Exhibit 57: GlaxoSmithKline's Key Antibacterial Drugs Portfolio
  • Exhibit 58: Share of Augmentin in GlaxoSmithKline's Antibacterial Drugs Segment Revenue 2013
  • Exhibit 59: Region-wise Segmentation of GlaxoSmithKline's Antibacterial Drugs 2013 (US$ million)
  • Exhibit 60: Geography-wise Segmentation of GlaxoSmithKline's Antibacterial Drugs 2013
  • Exhibit 61: Geography-wise Segmentation of GlaxoSmithKline's Antibacterial Drugs Segment 2013
  • Exhibit 62: GlaxoSmithKline's Key Anti HIV Drugs Portfolio (ViiV Healthcare)
  • Exhibit 63: Geography-wise Segmentation of GlaxoSmithKline's Key Anti HIV Drugs 2013
  • Exhibit 64: Geography-wise Segmentation of GlaxoSmithKline's Key Anti HIV Drugs 2013 (US$ million)
  • Exhibit 65: Geography-wise Segmentation GlaxoSmithKline's Anti HIV Drugs Segment 2013
  • Exhibit 66: Pfizer's Key Anti-infective Drugs Portfolio
  • Exhibit 67: Pfizer's Key Anti-infective Drug Sales 2011-2013
  • Exhibit 68: Share of F. Hoffmann-La Roche's Key Anti-infective Drugs 2013
  • Exhibit 69: Geography-wise Segmentation of Pegasys 2013
  • Exhibit 70: Geography-wise Segmentation of Tamiflu 2013
  • Exhibit 71: Share of Johnson & Johnson's Key Anti-infective Drugs 2013
  • Exhibit 72: Share of Johnson & Johnson's Anti-infective Drugs 2011-2013
  • Exhibit 73: Johnson & Johnson's Anti-infective Drugs Sales 2011-2013 (US$ million)
  • Exhibit 74: Johnson & Johnson: Drug-wise Sales Comparison of Anti-infective Drugs 2011-2013
  • Exhibit 75: Merck's Key Anti-infective Drugs Portfolio
  • Exhibit 76: Share of Merck's Key Anti-infective Drugs 2013
  • Exhibit 77: Share of Merck's Key Anti-infective Drugs 2011-2013
  • Exhibit 78: Share of Merck's Key Anti-infective Drugs 2011-2013 (US$ million)
  • Exhibit 79: Merck's Drug-wise Sales Comparison of Key Anti-infective Drugs 2011-2013
  • Exhibit 80: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 81: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 82: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
  • Exhibit 83: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
  • Exhibit 84: Gilead Sciences: Geographical Segmentation by Revenue 2013
  • Exhibit 85: GlaxoSmithKline plc: Business Segmentation 2013
  • Exhibit 86: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 87: GlaxoSmithKline plc: Sales by Geography 2013
  • Exhibit 88: GlaxoSmithKline plc: Pipeline Products 2013
  • Exhibit 89: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 90: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 91: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 92: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 93: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 94: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 95: Pfizer Inc.: Business Segmentation
  • Exhibit 96: Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 97: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 98: Pfizer Inc.: Revenue by Geography 2013
Back to Top